Barclays Maintains Overweight on Exelixis, Raises Price Target to $25

Exelixis, Inc. -1.51%

Exelixis, Inc.

EXEL

20.91

-1.51%

Barclays analyst Peter Lawson maintains Exelixis (NASDAQ: EXEL) with a Overweight and raises the price target from $24 to $25.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via